lyo NZYSupreme qPCR Probe Master Mix
avitag biotin blocking Blog cell proliferation reagent wst 1 ctgf elisa novex gel Product ros assay tbr2 antibody western blot control

lyo NZYSupreme qPCR Probe Master Mix

Description: Lyo NZYSupreme qPCR Probe Master Mix (2x) is an optimized and highly efficient freeze-dried reaction mixture developed for realtime PCR. This master mix was engineered with a dual hot-start enzyme control mechanism to provide the highest detection sensitivity. In addition, the latest developments in PCR enhancers have been incorporated in the Lyo NZYSupreme qPCR Probe Master Mix, including buffer chemistry and incorporation of highly robust engineered enzymes. This master mix does not contain ROX and it was specifically developed for probe-detection technology, including molecular beacons. For qPCR instruments that require ROX reference dye, please add ROX (Cat. No. MB406) according to the table presented in the section “ROX reference dye”. Lyo NZYSupreme qPCR Probe Master Mix (2x) is provided as a simple-to-use, stabilized 2x reaction mixture that includes all components for quantitative PCR, except sample DNA, primers, probe and water.

Features:
– Eco-friendly room temperature shipment
– Stable at room temperature for 1 month
– Dual hot-start mode
– Ultra-sensitive: detects low-copy number targets
– Batch-to-batch reproducibility
– Intra-batch reproducibility
– Simple and reproducible
– Compatible with multiple real-time platforms

Components:
– Lyo NZYSupreme qPCR Probe Master Mix (2x)
– qPCR master mix reconstitution buffer

Applications:
– Real-time qPCR
– Two-step RT-qPCR
– Developed for probe-detection technology

New Lyo qPCR Probe Master Mix (2x)

Lyo NZYSupreme qPCR Probe Master Mix (2x)

Description: Lyo NZYSupreme qPCR Probe Master Mix (2x) is an optimized and highly efficient freeze-dried reaction mixture developed for realtime PCR. This master mix was engineered with a dual hot-start enzyme control mechanism to provide the highest detection sensitivity. In addition, the latest developments in PCR enhancers have been incorporated in the Lyo NZYSupreme qPCR Probe Master Mix, including buffer chemistry and incorporation of highly robust engineered enzymes. This master mix does not contain ROX and it was specifically developed for probe-detection technology, including molecular beacons. For qPCR instruments that require ROX reference dye, please add ROX (Cat. No. MB406) according to the table presented in the section “ROX reference dye”. Lyo NZYSupreme qPCR Probe Master Mix (2x) is provided as a simple-to-use, stabilized 2x reaction mixture that includes all components for quantitative PCR, except sample DNA, primers, probe and water.

lyo NZYSupreme qPCR Probe Master Mix
lyo NZYSupreme qPCR Probe Master Mix

Features:
– Eco-friendly room temperature shipment
– Stable at room temperature for 1 month
– Dual hot-start mode
– Ultra-sensitive: detects low-copy number targets
– Batch-to-batch reproducibility
– Intra-batch reproducibility
– Simple and reproducible
– Compatible with multiple real-time platforms

Components:
– Lyo NZYSupreme qPCR Probe Master Mix (2x)
– qPCR master mix reconstitution buffer

AceQ qPCR Probe Master Mix

Q112-03 2500 rxn (20 μl/rxn)
EUR 646

HotTaq Probe qPCR Mix (ROX)

BT11001 250rxn
EUR 109
Description: High quality HotTaq polymerase for different PCR variations and downstream applications.

HotTaq Probe qPCR Mix (Capillary)

BT11003 250rxn
EUR 109
Description: High quality HotTaq polymerase for different PCR variations and downstream applications.

HotTaq Probe qPCR Universal Mix

BT11004 250rxn
EUR 123
Description: High quality HotTaq polymerase for different PCR variations and downstream applications.

AceQ U+ Probe Master Mix

Q113-02 500 rxn (20 μl/rxn)
EUR 267

AceQ U+ Probe Master Mix

Q113-03 2500 rxn (20 μl/rxn)
EUR 842

SYBR Green qPCR Master Mix

HY-K0501 5 mL (500 rxns)
EUR 263

RT Master Mix for qPCR

HY-K0510 1 mL (100 rxns)
EUR 291

HotTaq Probe qPCR Mix (no ROX)

BT11002 250rxn
EUR 109
Description: High quality HotTaq polymerase for different PCR variations and downstream applications.

Fast Probe Master Mix (200 rxn)

31005 2x1ML
EUR 234
Description: Minimum order quantity: 1 unit of 2x1ML

Fast Probe Master Mix (500 rxn)

31005-1 5x1ML
EUR 466
Description: Minimum order quantity: 1 unit of 5x1ML

Fast Probe Master Mix (5000 rxn)

31005-2 50x1ML
EUR 3871
Description: Minimum order quantity: 1 unit of 50x1ML

ChamQ Geno-SNP Probe Master Mix

Q811-02 500 rxn (20 μl/rxn)
EUR 277

ChamQ Geno-SNP Probe Master Mix

Q811-03 2500 rxn (20 μl/rxn)
EUR 923

2x SYBR Green qPCR Master Mix

B21202 5 mL
EUR 224
Description: Our 2x SYBR Green qPCR master mix performs toe to toe in all qPCR assays with the most well known brands on the market but surpases them significantly in cost-efficiency.

2x SYBR Green qPCR Master Mix

B21203 25 mL
EUR 856
Description: Our 2x SYBR Green qPCR master mix performs toe to toe in all qPCR assays with the most well known brands on the market but surpases them significantly in cost-efficiency.

AceQ Universal SYBR qPCR Master Mix

Q511-02 500 rxn (20 μl/rxn)
EUR 221

AceQ Universal SYBR qPCR Master Mix

Q511-03 2500 rxn (20 μl/rxn)
EUR 646

ChamQ Universal SYBR qPCR Master Mix

Q711-02 500 rxn (20 μl/rxn)
EUR 221

ChamQ Universal SYBR qPCR Master Mix

Q711-03 2500 rxn (20 μl/rxn)
EUR 646

Accuris qMax Probe No Rox qPCR Mix

PR2001-N-1000 1 PC
EUR 467.74
  • To order instruments in 115V / US plug please delete the 'E' off the order code.European 2 pin plugs will be supplied as standard, please request UK if required.

AceQ U+ Universal Probe Master Mix V2

Q513-02 500 rxn (20 μl/rxn)
EUR 267

AceQ U+ Universal Probe Master Mix V2

Q513-03 2500 rxn (20 μl/rxn)
EUR 842

SYBR Green qPCR Master Mix (High ROX)

HY-K0521 1 mL (100 rxns)
EUR 113

SYBR Green qPCR Master Mix (Low ROX)

HY-K0522 5 mL (500 rxns )
EUR 257

SYBR Green qPCR Master Mix (No ROX)

HY-K0523 5 mL (500 rxns )
EUR 257

miRNA Universal SYBR® qPCR Master Mix

MQ101-01 125 rxn(20 μl/rxn)
EUR 138

miRNA Universal SYBR® qPCR Master Mix

MQ101-02 500 rxn(20 μl/rxn)
EUR 242

 

 

t.spot covid
avitag biotin blocking cell proliferation reagent wst 1 ctgf elisa novex gel pcr machines Product tbr2 antibody western blot control

t.spot covid

HIGHLIGHTS

  • TSPOT.COVID is an ELISpot interferon gamma-release assay for SARS-CoV-2
  • TSPOT.COVID identifies a T cell response to SARS-CoV-2 spike S1 and N peptides
  • 2–8 weeks post SARS-CoV-2 diagnosis TSPOT.COVID detected 98% of infections
  • In comparison, immunoglobulin G (IgG) serology detected 83% of infections in the same period
  • Cellular immune response activated sooner and lasted longer than antibodies

Abstract

Objective

To evaluate the performance of the T-SPOT.COVID test for identifying SARS-CoV-2-responsive T-cells in participants with SARS-CoV-2 infection.

Methods

The T-SPOT.COVID test uses ELISpot interferon-gamma release assay (IGRA) methodology to measure T cell responses to SARS-CoV-2 spike S1 and nucleocapsid peptides. T-SPOT.COVID and anti-N immunoglobulin (Ig) G serology tests were performed on blood from 186 patients with nucleic acid amplification test (NAAT)-confirmed-SARS-CoV-2 infection and 100 control group participants.

Results

In the 2–8 weeks after NAAT-diagnosed SARS-CoV-2 infection, the T-SPOT.COVID test detected 98.4% (63 of 64) of infected participants, while anti-N IgG serology detected 82.8%. In the first 2 weeks after diagnosis, during adaptive immune response activation, there were less reactive T-SPOT.COVID responses (75.7%, 28 of 37 infected participants) and many less seropositive responses (32.4%). Response numbers tapered after 8 weeks; however, T-SPOT.COVID test continued to detect most participants with confirmed infection (83.6%, 56 of 67) and continued to out-perform serology (52.2%). T-SPOT.COVID response due to cross-reactive T cells was ruled out by demonstrating that, of 44 control group participants with T cells responsive to 4 human common cold coronavirus peptides, only 1 was T-SPOT.COVID reactive.

Conclusion

The T-SPOT.COVID test performed well in detecting SARS-CoV-2-sensitized T-cells over many months

Introduction

Long-term protection from infectious agents, such as the SARS-CoV-2 virus, is mediated by T cells and antibody-mediated immunity of the adaptive immune system (

Sette and Crotty, 2021

). The T-SPOT.COVID test was developed to identify the presence of SARS-CoV-2-responsive T cells.

T cells contribute to the understanding of SARS-CoV-2 infections in many ways. T cells can identify past SARS-CoV-2 infections at a time when PCR tests would be negative and antibodies levels may be waning (

Dan et al., 2021

;

Gudbjartsson et al., 2020

;

Poland et al., 2020

). T cells can provide immune memory lasting for months (

Dan et al., 2021

) and perhaps years, as suggested by the discovery of T cells to the SARS-CoV-1 coronavirus 17 years after infection (

Le Bert et al., 2020

). T cells may act independently of antibodies to control a SARS-CoV-2 infection, as shown by the recovery of COVID-19 patients who lack detectable antibodies but have SARS-CoV-2-responsive T cells (

Gallais et al., 2021

;

Sekine et al., 2020

). T cells also show reactivity to numerous SARS-CoV-2 epitopes, so have the potential to protect against many SARS-CoV-2 variants (

Grifoni et al., 2020

;

Tarke et al., 2021

). T cell-based assays can probe the longevity of an immune response following a SARS-CoV-2 infection or vaccination (

Goletti et al., 2021

;

Liu et al., 2021

;

Reynolds et al., 2021

). These various roles suggest that a T cell assay can be a key contributor to SARS-CoV-2 investigations.

The T-SPOT.COVID test, an enzyme-linked immunospot (ELISpot) assay, identifies T cells in peripheral blood that release interferon-gamma (IFN-γ) in response to stimulation with SARS-CoV-2 peptides. The T-SPOT.COVID test builds on the T-SPOT platform (Oxford Immunotec) used worldwide for tuberculosis and cytomegalovirus testing and the research version, the T-SPOT Discovery SARS-CoV-2 test (

Liu et al., 2021

;

t.spot covid
t.spot covid
Wyllie et al., 2021

). The T-SPOT.COVID ELISpot methodology is performed in many laboratories and offers a standardized comparison of T cell immunity among participants. In addition, ELISpot assays normalize the number of peripheral blood mononuclear cells (PBMCs), thus maintaining test effectiveness in participants with lymphopenia, a commonly reported condition in many COVID-19 patients (

Altmann and Boyton, 2020

) and immunosuppressed people.

The objective of this study was to evaluate the ability of the T-SPOT.COVID test to detect T cell responses in participants with or without a history of SARS-CoV-2 infection and to compare the T-SPOT.COVID test results with anti-N immunoglobulin (Ig)G serology results in the first several months after infection.

Materials and Methods

2.1 Participant recruitment

Participants for this single-center, cross-sectional study were recruited from patients who had attended the outpatient Primacare medical center in Fall River, Massachusetts, USA, between November 30, 2020, and March 24, 2021, a time of high demand for COVID-19 testing. Among other healthcare services, Primacare provided COVID-19 testing to anyone wanting or required to be tested. The New England Center for Clinical Research (NECCR) invited participants to join the study if they had received a positive SARS-CoV-2 nucleic acid amplification test (NAAT) at Primacare or if NECCR deemed them to be at low risk of SARS-CoV-2 infection. As this study was run independently from the participants’ healthcare providers, clinical data such as chest x-rays and hospitalizations records were not obtained. Informed consent and study approval were obtained from the Advarra institutional review board by NECCR at Primacare.
Confirmed-infection group: A NAAT, which detects the presence of the SARS-CoV-2 virus, was used to identify people infected with SARS-CoV-2 at the time of testing (

Rai et al., 2021

). Participants in the confirmed-infection group were recruited from asymptomatic and symptomatic patients who had had a positive SARS-CoV-2 NAAT result within the past 9 months. The date of the first positive NAAT result was considered the date of diagnosis of SARS-CoV-2 infection. Blood was drawn for Abbott SARS-CoV-2 chemiluminescent microparticle immunoassay (CMIA) anti-N IgG serology and T-SPOT.COVID tests between 0 to 249 days after diagnosis.

The analysis of responses was divided into 3 time periods: 0 to 2 weeks after diagnosis (0 to 14 days); 2+ to 8 weeks after diagnosis (15 to 56 days); and 8+ weeks after diagnosis (57+ days).
Control group: Many SARS-CoV-2 studies use frozen pre-pandemic blood for control samples; however, the T-SPOT platform requires fresh blood to ensure consistent results. Therefore fresh blood was obtained from control group participants prospectively recruited from individuals with low risk of prior SARS-CoV-2 infection. Requirements for enrollment included no current or prior signs or symptoms of COVID-19, no known contact with a confirmed SARS-CoV-2-infected individual, no prior history of a positive SARS-CoV-2 NAAT, no SARS-CoV-2 vaccination, and no prior diagnosis with SARS-CoV-1 or Middle Eastern Respiratory Syndrome (MERS). In addition, the BIOHIT HealthCare SARS-CoV-2 lateral flow anti-N IgM/IgG serology test was performed at enrollment, and the 1 person with a positive BIOHIT result was not enrolled. Blood was drawn at enrollment for testing with T-SPOT.COVID and the Abbott CMIA anti-N IgG serology test and anyone with a positive serology result was excluded from the control group.

2.2 T-SPOT.COVID test

The T-SPOT.COVID test includes over 250 SARS-CoV-2 peptides (15-mer peptides overlapping by 11 amino acids) in 2 antigen peptide pools; one pool contains peptides from the spike S1 protein, including the receptor-binding domain, and the other contains peptides from the nucleocapsid protein.
Blood samples for the T-SPOT.COVID test were processed and analyzed according to the manufacturer’s instructions. Briefly, blood samples were drawn into lithium heparin tubes which were shipped overnight to Oxford Immunotec (Abingdon, UK) in temperature-controlled shipping boxes. Next, the T-Cell Xtend reagent (Oxford Immunotec) was added to the samples, and PBMCs were isolated by density gradient centrifugation, washed, counted, and 250 000 cells/well were plated into 4 wells of a 96-well plate.

COVID-19 IgG/IgM Rapid Test Kit

UNCOV-20 20T/kit
EUR 155

Accu-Tell COVID-19 IgG/IgM Rapid Test

GEN-B352-20tests 20 tests
EUR 236
Description: A rapid test for detection of antibodies (IgG and IgM) for 2019-nCoV, the novel Coronavirus from the Wuhan strain. The test is easy to perform, takes 10 minutes to provide reliable results and is higly specific to the 2019-nCoV Coronavirus.

Accu-Tell COVID-19 IgG/IgM Rapid Test

GEN-B352-40tests 40 tests
EUR 321
Description: A rapid test for detection of antibodies (IgG and IgM) for 2019-nCoV, the novel Coronavirus from the Wuhan strain. The test is easy to perform, takes 10 minutes to provide reliable results and is higly specific to the 2019-nCoV Coronavirus.

Panbio™ COVID-19 IgG/IgM Rapid Test

ICO-T402 25 Tests/Kit
EUR 220

Panbio™ COVID-19 Ag Rapid Test Device

41FK10 25 Tests/Kit
EUR 138

Purified recombinant COVID-19 (isolate Wuhan-Hu-1) NP protein

nCoVNP-126V 100ug
EUR 792
Description: Purified recombinant COVID-19(isolate Wuhan-Hu-1) NP protein was expressed in HEK293 cells.

Recombinant COVID-19 (isolate Wuhan-Hu-1) S(ΔTM) protein

nCoVS-125V 100ug
EUR 792
Description: Purified recombinant COVID-19(isolate Wuhan-Hu-1) S(ΔTM) protein was expressed in HEK293 cells.

Novel Coronavirus COVID-19 (2019-nCoV) Real Time RT-PCR Kit

RR-0478-02 25 tests/kit
EUR 991
  • For use with PE5700, MJ-Opticon & other single color systems, ABI7000, ABI7300, ABI7500, ABI7900, ABI StepOne, StepOne plus, MJ-Opticon2, MJ-chromo4, MX3000P, MX3005P, Smart Cycler II, Rotor-Gene 6000, LightCycler 480, CFX 96, Life 96, Slan 96, iCycl
  • Show more
Description: Novel Coronavirus (2019-nCoV) Real Time RT-PCR Kit is used for the qualitative detection of a novel coronavirus, which was identified in 2019 at Wuhan City, Hubei Province, China, in upper respiratory tract specimens (nasopharyngeal extracts, deep cough sputum, etc.) and lower respiratory tract specimens (alveoli irrigation fluid, etc.) by real time PCR systems.

Novel Coronavirus COVID-19 (2019-nCoV) Real Time Multiplex RT-PCR Kit (Detection for 3 Genes )

RR-0479-02 25 tests/kit
EUR 1347
  • For use with PE5700, MJ-Opticon & other single color systems, ABI7000, ABI7300, ABI7500, ABI7900, ABI StepOne, StepOne plus, MJ-Opticon2, MJ-chromo4, MX3000P, MX3005P, Smart Cycler II, Rotor-Gene 6000, LightCycler 480, CFX 96, Life 96, Slan 96, iCycl
  • Show more
Description: Novel Coronavirus (2019-nCoV) Real Time Multiplex RT-PCR Kit is used for the qualitative detection of a novel coronavirus, which was identified in 2019 at Wuhan City, Hubei Province, China, in upper respiratory tract specimens (nasopharyngeal extracts, deep cough sputum, etc.) and lower respiratory tract specimens (alveoli irrigation fluid, etc.) by real time PCR systems. It detects N gene, E gene and RdRp gene of 2019-nCoV. RR-0479-02 has been also approverd by CFDA for emergency use and is WHO standard.
AIRBORNE ALLERGY SCREEN KIT
avitag biotin blocking cell proliferation reagent wst 1 ctgf elisa novex gel pcr machines Product ros assay tbr2 antibody western blot control

test for allergies airborne screen

Overview

During allergy skin tests, your skin is exposed to suspected allergy-causing substances (allergens) and is then observed for signs of an allergic reaction.

Along with your medical history, allergy tests may be able to confirm whether a particular substance you touch, breathe, or eat is causing symptoms.

 

Allergy skin tests are widely used to help diagnose allergic conditions, including:

  • Hay fever (allergic rhinitis)
  • Allergic asthma
  • Dermatitis (eczema)
  • Food allergies
  • Penicillin allergy
  • Bee venom allergy

Skin tests are generally safe for adults and children of all ages, including infants. In certain circumstances, though, skin tests aren’t recommended. Your doctor may advise against skin testing if you:

  • Have ever had a severe allergic reaction. You may be so sensitive to certain substances that even the tiny amounts used in skin tests could trigger a life-threatening reaction (anaphylaxis).
  • Take medications that could interfere with test results. These include antihistamines, many antidepressants and some heartburn medications. Your doctor may determine that it’s better for you to continue taking these medications than to temporarily discontinue them in preparation for a skin test.
  • Have certain skin conditions. If severe eczema or psoriasis affects large areas of skin on your arms and back — the usual testing sites — there may not be enough clear, uninvolved skin to do an effective test. Other skin conditions, such as dermatographism, can cause unreliable test results.

Blood tests (in vitro immunoglobulin E antibody tests) can be useful for those who shouldn’t or can’t undergo skin tests. Blood tests aren’t used for penicillin allergy.

In general, allergy skin tests are reliable for diagnosing allergies to airborne substances, such as pollen, pet dander and dust mites. Skin testing may help diagnose food allergies. But because food allergies can be complex, you may need additional tests or procedures.

Types of allergens

Allergens are substances that can cause an allergic reaction. There are three primary types of allergens:

  • Inhaled allergens affect the body when they come in contact with the lungs or membranes of the nostrils or throat. Pollen is the most common inhaled allergen.
  • Ingested allergens are present in certain foods, such as peanuts, soy, and seafood.
  • Contact allergens must come in contact with your skin to produce a reaction. An example of a reaction from a contact allergen is the rash and itching caused by poison ivy.

Allergy tests involve exposing you to a very small amount of a particular allergen and recording the reaction.

Insect sting allergy tests 

Why allergy testing is performed

Allergies affect more than 50 million people living in the USA, according to the American College of Allergy, Asthma, and Immunology. Inhaled allergens are by far the most common type. Seasonal allergies and hay fever, which is an allergic response to pollen, affect more than 40 million Americans.

The World Allergy Organization estimates that asthma is responsible for 250,000 deaths annually. These deaths can be avoided with proper allergy care, as asthma is considered an allergic disease process.

How allergy testing is performed

An allergy test may involve either a skin test or a blood test. You may have to go on an elimination diet if your doctor thinks you might have a food allergy.

AIRBORNE ALLERGY SCREEN KIT
AIRBORNE ALLERGY SCREEN KIT

Skin tests

Skin tests are used to identify numerous potential allergens. This includes airborne, food-related, and contact allergens. The three types of skin tests are scratch, intradermal, and patch tests.

Your doctor will typically try a scratch test first. During this test, an allergen is placed in liquid, then that liquid is placed on a section of your skin with a special tool that lightly punctures the allergen into the skin’s surface. You’ll be closely monitored to see how your skin reacts to the foreign substance. If there’s localized redness, swelling, elevation, or itchiness of the skin over the test site, you’re allergic to that specific allergen.

If the scratch test is inconclusive, your doctor may order an intradermal skin test. This test requires injecting a tiny amount of allergen into the dermis layer of your skin. Again, your doctor will monitor your reaction.

Another form of skin test is the patch test (T.R.U.E. TESTTrusted Source). This involves using adhesive patches loaded with suspected allergens and placing these patches on your skin. The patches will remain on your body after you leave your doctor’s office. The patches are then reviewed at 48 hours after application and again at 72 to 96 hours after application.

Blood tests

If there’s a chance you’ll have a severe allergic reaction to a skin test, your doctor may call for a blood test. The blood is tested in a laboratory for the presence of antibodies that fight specific allergens. This test, called ImmunoCAP, is very successful in detecting IgE antibodies to major allergens.

Elimination diet

An elimination diet may help your doctor determine which foods are causing you to have an allergic reaction. It entails removing certain foods from your diet and later adding them back in. Your reactions will help determine which foods cause problems.

 

 

Cobalt Rapid Run

6CoRR-25 25 ml
EUR 166

Cobalt Rapid Run

6CoRR-500 500 ml
EUR 1474

Nickel Rapid Run

6NiRR-100 100 ml
EUR 431

Nickel Rapid Run

6NiRR-25 25 ml
EUR 166

Nickel Rapid Run

6NiRR-500 500 ml
EUR 1474

Rapid Transformation Kit

156 Kit
EUR 158

YB Rapid Ligationkit

FYC003-100R 1 vial Ask for price

Calci-Clear Rapid

NAT1318 EACH
EUR 75

Calci-Clear Rapid

NAT1320 EACH
EUR 128

Calci-Clear Rapid

NAT1322 EACH
EUR 386

BASU RaPID plasmid

PVT14054 2 ug
EUR 599

Leptospira biflexa Antibody

abx023082-1ml 1 ml
EUR 565
  • Shipped within 5-10 working days.

Nickel NTA Rapid Run

6RR-NTANI-100 100 ml
EUR 815

Nickel NTA Rapid Run

6RR-NTANI-25 25 ml
EUR 262

Nickel NTA Rapid Run

6RR-NTANI-500 500 ml
EUR 3711

Metal Free Rapid Run

6RR-QH-100 100 ml
EUR 431

Metal Free Rapid Run

6RR-QH-25 25 ml
EUR 166

Metal Free Rapid Run

6RR-QH-500 500 ml
EUR 755

Melamine Rapid Test Kit

abx092011-50tests 50 tests
EUR 370
  • Shipped within 5-12 working days.

Rapid Antibody Purification Kit

AKR-160 10 assays
EUR 519
Description: Cell Biolabs? Rapid Antibody Purification kit is designed for rapid, single-step purification of high-quality IgG from ascites, serum and tissue culture media or hybridoma supernatants.

T4 DNA Ligase (Rapid)

N103-01 600,000 U
EUR 563

NDV rapid test kit

RG15-03 1 box
EUR 139.05
Description: Please check the datasheet of NDV rapid test kit before using the test.

IBD rapid test strip

RG15-04 10 boxes
EUR 148
Description: Please check the datasheet of IBD rapid test strip before using the test.

Rabies rapid test strip

RG18-01 10 boxes
EUR 151.92
Description: Please check the datasheet of Rabies rapid test strip before using the test.

Rapid RCA Assay Kit

VPK-111 30 assays
EUR 537
Description: Traditionally RCA (replication competent adenovirus) is measured in permissive cells by a plaque-forming unit (PFU) assay which takes 10-14 days. Our Rapid RCA Assay Kit uses an immunocytochemistry staining protocol that requires only a two day incubation.

Rapid RCA Assay Kit

VPK-111-5 5 x 30 assays
EUR 2155
Description: Traditionally RCA (replication competent adenovirus) is measured in permissive cells by a plaque-forming unit (PFU) assay which takes 10-14 days. Our Rapid RCA Assay Kit uses an immunocytochemistry staining protocol that requires only a two day incubation.

Recombinant Leptospira interrogans [His]

DAGA-3029 1mg
EUR 2665

Leptospira interrogans PCR kit

PCR-VH088-48D 50T
EUR 425.8
  • Contact us in order to know the reactivity of the kit.
Description: An conventional PCR kit for detection of Leptospira interrogans

Leptospira interrogans PCR kit

PCR-VH088-96D 100T
EUR 521.5
  • Contact us in order to know the reactivity of the kit.
Description: An conventional PCR kit for detection of Leptospira interrogans

Leptospira spp. PCR kit

PCR-VH089-48D 50T
EUR 425.8
  • Contact us in order to know the reactivity of the kit.
Description: An conventional PCR kit for detection of Leptospira spp.

Leptospira spp. PCR kit

PCR-VH089-96D 100T
EUR 521.5
  • Contact us in order to know the reactivity of the kit.
Description: An conventional PCR kit for detection of Leptospira spp.

H. Pylori Rapid Stain Kit

AYH-1 1 kit(s)
EUR 215

H. Pylori Rapid Stain Kit

AYH-2 100 Slides
EUR 132

DEAE Rapid Run Agarose Bead

DEAERR-25 25 ml
EUR 102

DEAE Rapid Run Agarose Bead

DEAERR-300 300 ml
EUR 492

Canine T4 Rapid ELISA Kit

DEIA1763 32T
EUR 832

ToxOut? Endotoxin Rapid Removal Agarose

7941-5
EUR 185

Melamine (MEL) Rapid Test Kit

abx092057-50tests 50 tests
EUR 370
  • Shipped within 5-12 working days.
Blog

Sars cov 2 binding antibodies

The immune response to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is initiated by innate immune activation followed by antigen-specific T and B cell responses. An important mechanism that protects against viral diseases is the presence of virus-neutralizing antibodies, which is similar for almost all viruses that cause acute illness followed by the elimination of pathogens.

Accordingly, all currently available antiviral vaccines are primarily intended to induce virus-neutralizing antibodies. Neutralizing antibodies generally block the binding of the virus to cell receptors.

In some cases, neutralizing antibodies can prevent the conformational changes necessary for virus fusion with the cell membrane or proteolytic cleavage. Neutralizing antibodies against SARS-CoV-2 are directed against the peak protein (S), which contains multiple antigenic epitopes in the receptor-binding domain (RBD) and non-RBD epitopes.

An important neutralization mechanism is to block the binding of RBD to angiotensin-converting enzyme 2 (ACE2), the virus’s cellular receptor. RBD is located at the tip of protein S. The receptor-binding motif (RBM) consists of approximately 70 aa within RBD and represents the actual amino acids that directly interact with ACE2.

Coronaviruses get their names from the typical spikes that are formed by the spike protein (S) that inserts into the lipid bilayer membrane of the virus. The receptor-binding domain (RBD) and its receptor-binding motif (RBM) allow interaction with the cell-surface receptor ACE2 that mediates entry of the virus into host cells.

This can be blocked by neutralizing antibodies. Therefore, most of the neutralizing epitopes are found on RBD / RBM. In addition to protein S, SARS-CoV-2 has two other viral surface proteins (not shown): envelope (E) and matrix (M).

Blog

Elastase from Porcine Pancreas

Related Categories: Application rate, Biochemicals and reagents, Enzymes, Inhibitors and substrates, Isolation of proteins and nucleic acids

Quality level: 100

Form: lyophilized

Specific activity: ≥25 units / mg protein

Storage condition:

OK to freeze
Dried

Storage conditions: -20C

General description

Elastase is native to the porcine pancreas. Serine protease that catalyzes the hydrolysis of proteins and peptides (especially at bonds adjacent to neutral amino acid residues), including albumin, casein, denatured collagen, elastin, fibrin, and hemoglobin, and of various synthetic substrates containing aspartic acid, phenylalanine, or tyrosine. Inhibited by DFP, elastin, and α2-macroglobulin.

Elastase is native to the porcine pancreas. Catalyzes the hydrolysis of proteins and peptides (especially at bonds adjacent to neutral amino acid residues), including albumin, casein, denatured collagen, elastin, fibrin, and hemoglobin, and of various synthetic substrates containing aspartic acid, glutamic acid, phenylalanine, or tyrosine. Preferably it cleaves peptide bonds at the carbonyl end of amino acid residues with small hydrophobic side chains, such as glycine, valine, leucine, isoleucine, and particularly alanine. Inhibited by DFP, elastin, and α2-macroglobulin. It has an optimal pH of 7.8-8.5; pI = 9.5.

Packaging

1000, 250 u in plastic ampoule

Warning

Toxicity: Standard handling (A)

Definition of unit

One unit is defined as the amount of enzyme that will hydrolyze 1.0 mole of Suc-Ala-Ala-Pro-Abu-PNA (catalog # 324699) per minute at 25 ° C, pH 8.0.

Physical form

Lyophilized from 50 mM trehalose, 1 mM acetic acid.

Reconstitution

After reconstitution, elastase can be stored at 4 ° C at pH 6.0 for long-term use. If incubated at room temperature at or near its optimum pH, elastase rapidly autolyzes to a mixture of peptides. Stock solutions are stable for up to 2 months at 4 ° C, pH 6.0.

Blog

ELHGHII – Human/Monkey IgG anti-human

General description

The product binds human IgG and not other human Ig. Immunoglobulins are composed of antigen-binding domains of two fragments (Fab) and one crystallizable fragment (Fc). The gene encoding the IgG gene cluster is found on human chromosome 14. Anti-human IgG antiserum (Fc specific) is produced in goat using purified human IgG, Fc fragment, as an immunogen. Affinity isolated antibody is obtained from goat anti-human IgG antiserum by immunospecific purification that removes essentially all goat serum proteins, including immunoglobulins, that do not specifically bind to the Fc fragment of human IgG.

Specificity

Specificity for the human IgG Fc fragment is determined by ELISA and immunoelectrophoresis (IEP). The antibody preparation is specific for human IgG, Fc fragment when tested against purified human IgA, IgG (Fc and Fab fragments), IgM, Bence Jones kappa, and Bence Jones lambda myeloma proteins. No reactivity is observed with the Fab fragment of human IgG, light chains, IgA or IgM. The affinity-purified anti-human IgG (Fc-specific) reagent offers the advantage of increased sensitivity for human IgG without cross-reactivity with other substances present on the cell membrane or surface.

The lack of cross-species cross-reactivity with mouse or rat serum proteins makes this product excellent for screening human monoclonal antibodies produced by hybridoma cells grown in vivo in mouse or rat ascites fluids. This product has the ability to detect all subclasses of human IgG in human biological fluids or tissues from normal or pathological situations such as cancer or autoimmune diseases. It is effective as a second antibody reagent in immunoassay procedures and can be used as a starting material for conjugates using enzymes or fluorescent dyes.

Immunogen

Anti-human IgG antiserum (Fc specific) is produced in goats using purified human IgG, Fc fragment, as an immunogen

Request

The anti-human IgG antibody (specific for Fc) produced in goats has been used:

  • in double capture ELISA to measure antiglobulin responses in the serum of transplant patients treated with monoclonal antibodies CD52 (CAMPATH-1G)
  • in the detection of IgG levels in patients with rheumatoid arthritis
  • in small bowel biopsies
  • in patients with acute myocardial infarction by immunoblotting

Physical form

The solution in 0.01 M phosphate-buffered saline, pH 7.4, containing 15 mM sodium azide

Storage and stability

For continuous use, store at 2-8 ° C for up to one month. For long-term storage, the solution can be frozen in working aliquots. Repeated freezing and thawing, or storing in “frost-free” freezers is not recommended. If slight cloudiness occurs after prolonged storage, rinse the solution by centrifugation before use.

Disclaimer

Unless otherwise stated in our catalog or other company documentation accompanying the product (s), our products are designed for research use only and are not to be used for any other purpose, including but not limited to commercial uses. unauthorized, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

Biochemical / Physiological Actions

The IgG antibody subtype is the most abundant of the serum immunoglobulins of the immune system. It is secreted by B cells and is found in blood and extracellular fluids and provides protection against infections caused by bacteria, fungi, and viruses. Maternal IgG is transferred to the fetus through the placenta, which is vital for the newborn’s immune defense against infection. Mutations in the Fc region of IgG are implicated in autoimmune diseases such as rheumatoid arthritis. Modified Fc proteins are of therapeutic importance for the treatment of autoimmune diseases.

Blog

Glypican-3 (GPC3), 1G12

Immunogen: Recombinant fragment containing amino acids 511-580 of human Glypican 3 (1G12); Full-length recombinant human GPC3 protein (GPC3 / 863)

Location: Cytoplasmic

Marker: Hepatocellular carcinoma marker

Specificity

Glypican-3 (GPC3) is an integral membrane protein that is mutated in Simpson-Golabi-Behmel syndrome (GBSS). SGBS is characterized by pre-and postnatal overgrowth and is an X-linked recessive condition. GPC3 can also be found in secreted form. Anti-GPC3 has been identified as a useful tumor marker for the diagnosis of hepatocellular carcinoma (HCC), hepatoblastoma, melanoma, testicular germ cell tumors, and Wilms tumor.

In HCC patients, GPC3 is overexpressed in neoplastic liver tissue and elevated in serum, but is undetectable in normal liver, benign liver, and serum from healthy donors. GPC3 expression is also found to be higher in HCC liver tissue than in cirrhotic liver or liver with focal lesions such as dysplastic nodules and areas of liver adenoma (HA) with malignant transformation. In the context of testicular germ cell tumors, GPC3 expression is up-regulated in certain histological subtypes, specifically yolk sac tumors and choriocarcinoma.

 

A high level of GPC3 expression has also been found in some types of embryonal tumors, such as Wilm’s tumor and hepatoblastoma, with low or undetectable expression in adjacent normal tissue. In thyroid cancer patients, GPC3 expression is dramatically improved in certain types of cancers: 100% in follicular carcinoma and 70% in papillary carcinoma. The expression of GPC3 in follicular carcinoma was significantly higher than that of follicular adenoma. In contrast, GPC 3 is not expressed in anaplastic carcinoma.

Isotype: IgG

Clonality: Monoclonal

Host: Mouse

Gene: GPC3

Purity: Purified Protein A or G

Innovator’s reward: Try on a species/app not listed above to receive a full credit towards a future purchase.

Applications / Dilutions

Dilutions

  • Flow cytometry 0.5 – 1 ug / million cells in 0.1 ml
  • Immunocytochemistry / Immunofluorescence 1-2 ug / ml
  • Immunohistochemistry
  • Immunohistochemistry-Paraffin 0.5 – 1.0 ug / ml
  • Immunofluorescence 0.5 – 1.0 ug / ml

Application notes

  • Immunohistochemistry (formalin-fixed): 1-2 ug/ml for 30 minutes at RT. Staining of formalin-fixed tissues requires heating tissue sections in 1 mM EDTA buffer, pH 7.5-8.5, for 45 min at 95 ° C followed by cooling at RT for 20 min.
  • The optimal dilution for a specific application must be determined.

Theoretical MW

  • 67 kDa.
  • Disclaimer Note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post-translational modifications, post-translation cleavages, relative charges, and other experimental factors.

Packaging, storage, and formulations

Storage: Store at 4C.

Buffer: 10 mM PBS with 0.05% BSA

Preservative: 0.05% sodium azide

Concentration: 0.2mg / ml

Purity: Purified Protein A or G

Alternative names for the Glypican 3 antibody (1G12 + GPC3 / 863)

  • DGSX
  • Glypican 3
  • glypican 3 proteoglycan
  • glypican-3
  • GPC3
  • GTR2-2
  • proteoglycan heparan sulfate
  • OCI-5 intestinal protein
  • MXR7
  • OCI5
  • OCI-5
  • glypican-3 secreted
  • SGB
  • SGBS
  • SGBS1SDYS

Limitations

This product is for research use only and is not approved for human use or clinical diagnosis. Primary Antibodies are guaranteed for 1 year from the date of receipt.

Blog

Anti-Human Glycan-3 25 µg

Resume

Anti-glycan antibodies are an abundant subpopulation of serum antibodies with critical functions in many immune processes. Changes in the levels of these antibodies can occur with the onset of disease, exposure to pathogens, or vaccination. As a result, there has been significant interest in exploiting anti-glycan antibodies as biomarkers for many diseases. The serum contains a mixture of anti-glycan antibodies that can recognize the same antigen, and competition for binding can potentially influence the detection of antibody subpopulations that are more relevant to disease processes.

The most abundant antibody isotypes in serum are IgG, IgM, and IgA, but little is known about how these different isotypes compete for the same glucan antigen. In this study, we developed a multiplexed glucan microarray assay and applied it to assess how different isotypes of anti-glucan antibodies (IgA, IgG, and IgM) compete for the imprinted glycan antigens. While IgG and IgA antibodies generally outperform IgM for peptide or protein antigens, we found that IgM outperformed IgG and IgA on many glucan antigens.

To illustrate the importance of this effect, we provide evidence that IgM competition may explain the unexpected observation that IgG of certain antigenic specificities appears to be preferentially transported from mothers to fetuses. We show that IgM in maternal serum competes with IgG resulting in lower than expected IgG signals. Since cord blood contains very low levels of IgM, competition only affects maternal IgG signals, making it appear that certain IgG antibodies are higher in cord blood than matched maternal blood. Taken together, the results highlight the importance of competition for studies involving anti-glycan antibodies.

Introduction

Human serum contains a wide variety of carbohydrate-binding antibodies that play a critical role in human health and provide a rich pool of potential biomarkers for many biomedical applications and diseases. For example, the detection of anti-glycan antibodies against blood group A and B antigens provides a simple and reliable strategy to predict which individuals are suitable for transfusion and transplantation. Anti-glycan antibodies are also crucial in other areas of immunology, such as tumor surveillance, autoimmunity, defense against pathogens, and response to vaccines.

These broader immune functions have stimulated interest in exploring the potential use of circulating anti-glycan antibodies as biomarkers for a wide variety of diseases. Detection of antiglycan antibodies in serum is typically carried out by immobilizing a carbohydrate of interest, capturing specific antibodies, and then measuring the amounts of bound antibodies.

This process is complicated by the fact that serum often contains a mixture of antibodies that recognize the same antigen, and certain antibodies within the mixture may be more relevant to immune protection or disease processes than others. Antibodies against a particular glycan can vary in terms of affinity, specificity, concentration, and/or isotype, but they can all compete to bind to the same antigen. As a result, the binding of one can influence the detection of the others, and it can be difficult to reliably measure a subpopulation of target antibodies of interest.

Results

Our approach to assessing competence involved the use of purified IgG, IgA, and IgM antibodies from pooled human serum. Each polyclonal antibody sample would be profiled on our glycan microarray individually and in the presence of other isotypes. In addition, changes in IgG and IgM anti-glycan antibody signals would be assessed in whole serum after the addition of IgG, IgA, and IgM. Although IgD and IgE are also present in serum at low concentrations and capable of competing, this study focused on the most abundant antibodies in serum.